<DOC>
	<DOCNO>NCT01570608</DOCNO>
	<brief_summary>Ranibizumab proven effective large multicentre study . However , injection repeat monthly . A combined therapy establish photodynamic therapy might even effective , less intravitreal injection might necessary due synergistic effect . The study conduct explore whether intravitreal ranibizumab monotherapy combination verteporfin photodynamic therapy new time regime effective , safe convenient treatment patient subfoveal Choroidal Neovascularisation ( CNV ) secondary Age-Related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Lucentis KAV Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>BCVA letter score study eye 7324 ( approximately 20/40 20/320 ) use ETDRS chart measure 4 meter Snellen equivalent CNV lesion type study eye meet follow characteristic determine fluorescein angiography : Evidence CNV extend geometric center foveal avascular zone . The area CNV must occupy least 50 % total lesion . The lesion must ≤ 5400 micron great linear dimension ( GLD ) For occult classic CNV , additionally recent disease progression assess Investigator require define least one follow criterion : Blood associate lesion baseline Loss VA previous 3 month define either ≥ 5 letter ( ETDRS equivalent ) determine protocol refraction protocol measurement , 2 line use Snellen equivalent chart standard examination . ≥ 10 % increase great diameter lesion previous 3 month assess fluorescein angiography Willing return schedule visit 12 month period Only one eye assess study . If eye eligible , one bad visual acuity select treatment study unless , base medical reason , investigator deems eye appropriate candidate treatment study Patients BCVA &lt; 33 letter ( approximately 20/200 ) eye Prior treatment study eye verteporfin , externalbeam radiation therapy , vitrectomy , submacular surgery , surgical intervention AMD , transpupillary thermotherapy Previous current intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection device implantation ) study eye Focal laser photocoagulation ( juxta , extra subfoveal ) study eye Concomitant use chronic NSAIDs steroid ( route ) duration study participation ( chronic use define multiple dos take daily three consecutive day time study ) . Note ASA ( aspirin ) take `` low dose '' 100 mg qd prophylaxis MI and/or stroke permit study Current use likely need systemic medication know toxic lens , retina optic nerve , include Deferoxamine , Chloroquine/ hydroxychloroquine ( Plaquenil ) , Tamoxifen , Phenothiazines Ethambutol exclude History glaucoma filtration surgery , corneal transplant surgery extracapsular extraction cataract phacoemulsification within six month precede Day One , history postoperative complication within last 12 month precede Day One study eye ( uveitis , cyclitis etc . ) History uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment topical antiglaucomatous mediation ) . Aphakia absence posterior capsule study eye Previous violation posterior capsule study eye also exclude unless occur result YAG posterior capsulotomy association prior , posterior chamber intraocular lens implantation Spherical equivalent refractive error study eye demonstrate 8 diopter myopia Presence retinal pigment epithelial tear involve macula study eye Angioid streak precursor CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Active intraocular inflammation ( grade trace ) study eye Any active infection involve eyeball adnexa Vitreous hemorrhage history rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Ranibizumab</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Verteporfin</keyword>
	<keyword>age-related macular degeneration</keyword>
</DOC>